



FULBRIGHT & JAWORSKI L.L.P.


A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

SHIGHLANDER@FULBRIGHT.COM
PARTNER
DIRECT DIAL: (512) 536-3184

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

1632 BOWSER
LFW

September 28, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
<u>September 28, 2004</u> Date	 _____ Steven L. Highlander

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: Serial Number 10/043,658 entitled "METHODS FOR PREVENTING CARDIAC HYPERTROPHY AND HEART FAILURE BY INHIBITION OF MEF2 TRANSCRIPTION FACTOR INHIBITOR" by Eric N. Olson
Our ref: MYOG:024USC1

Commissioner:

Enclosed for filing in the above-referenced patent application is:

1. Request for Reconsideration Under 37 C.F.R. § 1.111;
2. Statement as Required Under 37 C.F.R. § 1.821(f), CRF and Paper Copy of Sequence Listing; and
3. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

25458528.1 / 10200023


COMMISSIONER FOR PATENTS

September 28, 2004

Page 2

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/MYOG:024USC1/SLH.

Very truly yours,



Steven L. Highlander

SLH/cpj

Encl: As noted